Processing

Please wait...

Settings

Settings

Goto Application

1. WO2020223327 - ANTIGEN SPECIFIC CD19-TARGETED CAR-T CELLS

Publication Number WO/2020/223327
Publication Date 05.11.2020
International Application No. PCT/US2020/030435
International Filing Date 29.04.2020
IPC
C07K 16/28 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
C07K 16/46 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
46Hybrid immunoglobulins
C12N 5/0783 2010.01
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
5Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
07Animal cells or tissues
071Vertebrate cells or tissues, e.g. human cells or tissues
078Cells from blood or from the immune system
0783T cells; NK cells; Progenitors of T or NK cells
A61K 35/28 2015.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
28Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
A61K 39/395 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
A61P 35/02 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
02specific for leukemia
Applicants
  • ATARA BIOTHERAPEUTICS, INC. [US]/[US]
Inventors
  • AFTAB, Blake, T.
Agents
  • HALSTEAD, David, P.
  • ABELLEIRA, Susan, M.
  • AKHIEZER, Alexander
  • CAI, Mi
  • HALSTEAD, David, P.
Priority Data
62/840,77430.04.2019US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) ANTIGEN SPECIFIC CD19-TARGETED CAR-T CELLS
(FR) CELLULES CAR-T CIBLÉES PAR UN ANTIGÈNE CD19 SPÉCIFIQUE
Abstract
(EN)
Disclosed are compositions and methods for targeted treatment of cancer, such as hematologic cancer. In particular, chimeric antigen receptor (CAR) T cells are disclosed that can be used with adoptive cell transfer to target and kill cancer cells with reduced antigen escape. Therefore, also disclosed are methods of providing an anti-tumor immunity in a subject with hematologic cancer that involves adoptive transfer of the disclosed CAR T cells.
(FR)
La présente invention concerne des compositions et des méthodes de traitement ciblé de cancers, notamment le cancer hématologique. En particulier, l'invention concerne des cellules T à récepteurs antigéniques chimériques (CAR) qui peuvent être utilisés dans le transfert adoptif de cellules pour cibler et éliminer des cellules cancéreuses avec un échappement antigénique réduit. L'invention concerne par ailleurs des procédés consistant à conférer une immunité anti-tumorale à un sujet atteint d'un cancer hématologique impliquant un transfert adoptif des cellules CAR-T décrites.
Latest bibliographic data on file with the International Bureau